Gender-Based Clinical, Therapeutic Strategies and Prognosis Differences in Atrial Fibrillation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Population
2.2. Variables Collected
2.3. Follow-Up
2.4. Statistical Analysis
3. Results
3.1. Baseline Characteristics of the Study Population
3.2. Gender-Based Clinical Differences at Index Episode
3.3. Healthcare Resource Use and Therapeutic Differences
3.4. Comparison of Long-Term Adverse Events
3.5. Multivariate Analysis of Mortality
4. Discussion
4.1. Possible Mechanisms Involved
4.2. Study Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lippi, G.; Sanchis-Gomar, F.; Cervellin, G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int. J. Stroke 2021, 16, 217–221. [Google Scholar] [CrossRef] [PubMed]
- EUGenMed Cardiovascular Clinical Study Group; Regitz-Zagrosek, V.; Oertelt-Prigione, S.; Prescott, E.; Franconi, F.; Gerdts, E.; Foryst-Ludwig, A.; Maas, A.H.; Kautzky-Willer, A.; Knappe-Wegner, D. Gender in cardiovascular diseases: Impact on clinical manifestations, management, and outcomes. Eur. Heart J. 2016, 37, 24–34. [Google Scholar]
- Chugh, S.S.; Havmoeller, R.; Narayanan, K.; Singh, D.; Rienstra, M.; Benjamin, E.J.; Gillum, R.F.; Kim, Y.H.; McAnulty, J.H., Jr.; Zheng, Z.J.; et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation 2014, 129, 837–847. [Google Scholar] [CrossRef] [PubMed]
- Andrade, J.G.; Deyell, M.W.; Lee, A.Y.K.; Macle, L. Sex Differences in Atrial Fibrillation. Can. J. Cardiol. 2018, 34, 429–436. [Google Scholar] [CrossRef] [PubMed]
- Cove, C.L.; Albert, C.M.; Andreotti, F.; Badimon, L.; Van Gelder, I.C.; Hylek, E.M. Female sex as an independent risk factor for stroke in atrial fibrillation: Possible mechanisms. Thromb. Haemost. 2014, 111, 385–391. [Google Scholar] [PubMed]
- Arnson, Y.; Hoshen, M.; Berliner Senderey, A.; Reges, O.; Balicer, R.; Leibowitz, M.; Avgil Tsadok, M.; Haim, M. Comparing Management and Outcomes in Men and Women with Nonvalvular Atrial Fibrillation: Data from a Population-Based Cohort. JACC Clin. Electrophysiol. 2018, 4, 604–614. [Google Scholar] [CrossRef]
- Cheng, E.Y.; Kong, M.H. Gender Differences of Thromboembolic Events in Atrial Fibrillation. Am. J. Cardiol. 2016, 117, 1021–1027. [Google Scholar] [CrossRef]
- Piccini, J.P.; Simon, D.N.; Steinberg, B.A.; Thomas, L.; Allen, L.A.; Fonarow, G.C.; Gersh, B.; Hylek, E.; Kowey, P.R.; Reiffel, J.A. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. JAMA Cardiol. 2016, 1, 282–291. [Google Scholar] [CrossRef]
- Kloosterman, M.; Chua, W.; Fabritz, L.; Al-Khalidi, H.R.; Schotten, U.; Nielsen, J.C.; Piccini, J.P.; Di Biase, L.; Häusler, K.G.; Todd, D.; et al. Sex differences in catheter ablation of atrial fibrillation: Results from AXAFA-AFNET 5. Europace 2020, 22, 1026–1035. [Google Scholar] [CrossRef]
- Lehto, M.; Haukka, J.; Aro, A.; Halminen, O.; Putaala, J.; Linna, M.; Mustonen, P.; Kinnunen, J.; Kouki, E.; Niiranen, J.; et al. Comprehensive nationwide incidence and prevalence trends of atrial fibrillation in Finland. Open Heart 2022, 9, e002140. [Google Scholar] [CrossRef]
- Samim, D.; Choffat, D.; Vollenweider, P.; Waeber, G.; Marques-Vidal, P.; Méan, M. Prevalence of atrial fibrillation: The Swiss population-based CoLaus|PsyCoLaus study. Herz 2023, 48, 48–54. [Google Scholar] [CrossRef] [PubMed]
- Turakhia, M.P.; Guo, J.D.; Keshishian, A.; Delinger, R.; Sun, X.; Ferri, M.; Russ, C.; Cato, M.; Yuce, H.; Hlavacek, P. Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States. Clin. Cardiol. 2023, 46, 484–493. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Johnsen, S.P.; Guo, Y.; Lip, G.Y.H. Epidemiology of Atrial Fibrillation: Geographic/Ecological Risk Factors, Age, Sex, Genetics. Card. Electrophysiol. Clin. 2021, 13, 1–23. [Google Scholar] [CrossRef] [PubMed]
- Bhave, P.D.; Lu, X.; Girotra, S.; Kamel, H.; Vaughan Sarrazin, M.S. Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm. 2015, 12, 1406–1412. [Google Scholar] [CrossRef] [PubMed]
- Potpara, T.S.; Marinkovic, J.M.; Polovina, M.M.; Stankovic, G.R.; Seferovic, P.M.; Ostojic, M.C.; Lip, G.Y. Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: The Belgrade atrial fibrillation study. Int. J. Cardiol. 2012, 161, 39–44. [Google Scholar] [CrossRef] [PubMed]
- Rienstra, M.; Vermond, R.A.; Crijns, H.J.G.M.; Tijssen, J.G.P.; Van Gelder, I.C.; RACE Investigators. Asymptomatic persistent atrial fibrillation and outcome: Results of the RACE study. Heart Rhythm. 2014, 11, 939–945. [Google Scholar] [CrossRef]
- Durán-Bobín, O.; Elices-Teja, J.; González-Melchor, L.; Vázquez-Caamaño, M.; Fernández-Obanza, E.; González-Babarro, E.; Cabanas-Grandío, P.; Piñeiro-Portela, M.; Prada-Delgado, O.; Gutiérrez-Feijoo, M.; et al. Differences in the Clinical Profile and Management of Atrial Fibrillation According to Gender. Results of the REgistro GallEgo Intercéntrico de Fibrilación Auricular (REGUEIFA) Trial. J. Clin. Med. 2021, 10, 3846. [Google Scholar] [CrossRef]
- Alegret, J.M.; Viñolas, X.; Martínez-Rubio, A.; Pedrote, A.; Beiras, X.; García-Sacristán, J.F.; Crespo-Mancebo, F.; Ruiz-Mateas, F. Gender Differences in Patients with Atrial Fibrillation Undergoing Electrical Cardioversion. J. Womens Health 2015, 24, 466–470. [Google Scholar] [CrossRef]
- Gurevitz, O.T.; Varadachari, C.J.; Ammash, N.M.; Malouf, J.F.; Rosales, A.G.; Herges, R.M.; Bruce, C.J.; Somers, V.K.; Hammill, S.C.; Gersh, B.J.; et al. The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion. Am. Heart J. 2006, 152, 155-e9–155-e13. [Google Scholar] [CrossRef]
- Grönberg, T.; Hartikainen, J.E.; Nuotio, I.; Biancari, F.; Vasankari, T.; Nikkinen, M.; Ylitalo, A.; Airaksinen, K.J. Can we predict the failure of electrical cardioversion of acute atrial fibrillation? The FinCV study. Pacing Clin. Electrophysiol. 2015, 38, 368–375. [Google Scholar] [CrossRef]
- O’Neal, W.T.; Sandesara, P.; Hammadah, M.; Venkatesh, S.; Samman-Tahhan, A.; Kelli, H.M.; Soliman, E.Z. Gender Differences in the Risk of Adverse Outcomes in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction. Am. J. Cardiol. 2017, 119, 1785–1790. [Google Scholar] [CrossRef]
- Kassim, N.A.; Althouse, A.D.; Qin, D.; Leef, G.; Saba, S. Gender differences in management and clinical outcomes of atrial fibrillation patients. J. Cardiol. 2017, 69, 195–200. [Google Scholar] [CrossRef] [PubMed]
- Marijon, E.; Le Heuzey, J.Y.; Connolly, S.; Yang, S.; Pogue, J.; Brueckmann, M.; Eikelboom, J.; Themeles, E.; Ezekowitz, M.; Wallentin, L.; et al. Causes of death and influencing factors in patients with atrial fibrillation: A competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013, 128, 2192–2201. [Google Scholar] [CrossRef] [PubMed]
- Hindricks, G.; Potpara, T.; Dagres, N.; Arbelo, E.; Bax, J.J.; Blomström-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.A.; Dilaveris, P.E.; et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2021, 42, 373–498. [Google Scholar] [CrossRef] [PubMed]
- Stewart, S.; Hart, C.L.; Hole, D.J.; McMurray, J.J.V. A population-based study of the long- term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 2002, 113, 359–364. [Google Scholar] [CrossRef] [PubMed]
- Benjamin, E.J.; Wolf, P.A.; D’Agostino, R.B.; Silbershatz, H.; Kannel, W.B.; Levy, D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998, 98, 946–952. [Google Scholar] [CrossRef]
- Bhupathy, P.; Haines, C.D.; Leinwand, L.A. Influence of sex hormones and phytoestrogens on heart disease in men and women. Womens Health 2010, 6, 77–95. [Google Scholar] [CrossRef]
- Odening, K.E.; Deiß, S.; Dilling-Boer, D.; Didenko, M.; Eriksson, U.; Nedios, S.; Ng, F.S.; Roca Luque, I.; Sanchez Borque, P.; Vernooy, K.; et al. Mechanisms of sex differences in atrial fibrillation: Role of hormones and differences in electrophysiology, structure, function, and remodelling. Europace 2019, 21, 366–376. [Google Scholar] [CrossRef]
- Masuda, M.; Matsuda, Y.; Uematsu, H.; Sugino, A.; Ooka, H.; Kudo, S.; Fujii, S.; Asai, M.; Iida, O.; Okamoto, S.; et al. Gender Differences in Atrial Fibrosis and Cardiomyopathy Assessed by Left Atrial Low-Voltage Areas During Catheter Ablation of Atrial Fibrillation. Am. J. Cardiol. 2023, 203, 37–44. [Google Scholar] [CrossRef]
- Preda, A.; Giordano, F.; Giani, V.; Guarracini, F.; Mazzone, P. Accelerated adverse atrial remodeling in women with atrial fibrillation: Results from studies using electroanatomic mapping systems. Am. J. Cardiol. 2023, 203, 524–525. [Google Scholar] [CrossRef]
- Bah, A.; Nuotio, I.; Grönberg, T.; Ylitalo, A.; Airaksinen, K.E.J.; Hartikainen, J.E.K. Sex, age, and time to cardioversion. Risk factors for cardioversion of acute atrial fibrillation from the FinCV study. Ann. Med. 2017, 49, 254–259. [Google Scholar] [CrossRef] [PubMed]
- Kostopoulou, A.; Zeljko, H.M.; Bogossian, H.; Ciudin, R.; Costa, F.; Heijman, J.; Kochhaeuser, S.; Manola, S.; Scherr, D.; Sohal, M.; et al. Atrial fibrillation-related stroke in women: Evidence and inequalities in epidemiology, mechanisms, clinical presentation, and management. Clin. Cardiol. 2020, 43, 14–23. [Google Scholar] [CrossRef] [PubMed]
- Gleason, K.T.; Himmelfarb, C.R.; Ford, D.E.; Lehmann, H.; Samuel, L.; Jain, S.; Naccarelli, G.; Aggarwal, V.; Nazarian, S. Association of sex and atrial fibrillation therapies with patient-reported outcomes. Heart 2019, 105, 1642–1648. [Google Scholar] [CrossRef] [PubMed]
- Kirchhof, P.; Camm, A.J.; Goette, A.; Brandes, A.; Eckardt, L.; Elvan, A.; Fetsch, T.; van Gelder, I.C.; Haase, D.; Haegeli, L.M.; et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N. Engl. J. Med. 2020, 383, 1305–1316. [Google Scholar] [CrossRef]
Total (n = 2013) | Male (n = 800) | Female (n = 1213) | p-Value | |
---|---|---|---|---|
Demographic data | ||||
Age (years) | 75 ± 12.6 | 70.86 ± 14.1 | 77.8 ± 10.6 | <0.001 |
<65 | 369 (18.3%) | 233 (29.1%) | 136 (11.2%) | |
65–74 | 430 (21.4%) | 172 (21.5%) | 258 (21.3%) | |
75–84 | 744 (37%) | 278 (34.8%) | 466 (38.4%) | |
>85 | 470 (23.3%) | 117 (14.6%) | 353 (29.1%) | |
Comorbidities | ||||
Hypertension | 1530 (76%) | 551 (68.9%) | 979 (80.7%) | <0.001 |
T2DM | 734 (36.46%) | 273 (34.1%) | 461 (38%) | 0.077 |
Smoking | 203 (10.1%) | 162 (20.3%) | 41 (3.4%) | <0.001 |
Obesity | 171 (8.5%) | 55 (6.9%) | 116 (9.6%) | 0.034 |
OSA | 78 (3.9%) | 44 (5.5%) | 34 (2.8%) | 0.002 |
Dyslipidemia | 177 (8%) | 288 (36%) | 513 (42.3%) | 0.005 |
Alcohol abuse | 801 (39.8%) | 29 (3.6%) | 3 (0.2%) | <0.001 |
COPD | 32 (1.6%) | 130 (16.3%) | 47 (3.9%) | <0.001 |
CKD | 231 (11.5%) | 92 (11.5%) | 139 (11.5%) | 0.978 |
PAD | 96 (4.8%) | 58 (7.3%) | 38 (3.1%) | <0.001 |
Stroke | 104 (5.2%) | 81 (10.1%) | 126 (10.4%) | 0.850 |
Structural Heart disease | ||||
HF | 400 (19.9%) | 130 (16.3%) | 270 (22.3%) | 0.001 |
Prior AMI | 158 (7.8%) | 85 (10.6%) | 73 (6%) | <0.001 |
AVD | 157 (7.8%) | 56 (7.0%) | 101 (8.3%) | 0.277 |
MVD | 221 (11%) | 68 (8.5%) | 153 (12.6%) | 0.004 |
DCM | 71 (3.5%) | 49 (6.1%) | 22 (1.8%) | <0.001 |
ICM | 184 (9.1%) | 89 (11.1%) | 95 (7.8%) | 0.012 |
HCM | 95 (4.7%) | 40 (5%) | 55 (4.5%) | 0.630 |
LVEF | 49.43 ± 13.43 | 46.0 ± 14.7 (n = 97) | 52.4 ± 11.4 (n = 111) | 0.001 |
Prior AF known | ||||
AF (all types) | 876 (43.52%) | 316 (39.5%) | 560 (46.2%) | 0.003 |
Paroxysmal | 216 (10.7%) | 78 (9.8%) | 138 (14.4%) | 0.341 |
Persistent | 123 (6.1%) | 48 (6,2%) | 75 (6%) | 0.478 |
Permanent | 204 (10.1%) | 73 (9.1%) | 131 (10.8%) | 0.344 |
CHA2DS2-VASc score | ||||
Average | 2.7 ± 1.6 | 4.2 ± 1.4 | <0.001 | |
HASBLED Scale | ||||
Average | 2.5 ± 1.14 (n = 533) | 2.6 ± 1.01 (n = 332) | 0.578 |
Male (n = 800) | Female (n = 1213) | p-Value | |
---|---|---|---|
Asymptomatic | 72 (9%) | 63 (5.3%) | 0.007 |
Chest pain | 162 (20.3%) | 281 (23.2%) | 0.122 |
Palpitations | 202 (25.3%) | 406 (33.5%) | <0.001 |
HF | 209 (26.1%) | 401 (33.1%) | 0.001 |
APE | 25 (3.1%) | 61 (5%) | 0.039 |
Dizziness | 131 (16.4%) | 165 (13.6%) | 0.086 |
Asthenia | 47 (5.9%) | 94 (7.7%) | 0.107 |
Syncope | 39 (4.9%) | 52 (4.3%) | 0.534 |
Hemodynamic instability | 11 (1.4%) | 31 (2.6%) | 0.070 |
HR at admission | 117.69 ± 34.665 | 122.41 ± 31.333 | 0.002 |
B | SE | Wald | p-Value | HR | 95.0% CI for Exp(B) | ||
---|---|---|---|---|---|---|---|
Lower | Upper | ||||||
Gender (Female) | 0.297 | 0.118 | 6.287 | 0.012 | 1.346 | 1.067 | 1.697 |
Age | 0.017 | 0.006 | 9.272 | 0.002 | 1.017 | 1.006 | 1.028 |
CKD | −0.310 | 0.151 | 4.222 | 0.040 | 0.733 | 0.546 | 0.986 |
AMI | 0.394 | 0.161 | 5.959 | 0.015 | 1.483 | 1.081 | 2.035 |
Previous HF | 0.561 | 0.118 | 22.460 | 0.000 | 1.753 | 1.390 | 2.211 |
DCM | 0.563 | 0.209 | 7.260 | 0.007 | 1.756 | 1.166 | 2.645 |
HCM | 0.474 | 0.188 | 6.343 | 0.012 | 1.607 | 1.111 | 2.324 |
CHA2DS2-VASc | 0.094 | 0.043 | 4.729 | 0.030 | 1.099 | 1.009 | 1.196 |
Mitral regurgitation | 0.509 | 0.130 | 15.250 | 0.000 | 1.664 | 1.289 | 2.148 |
95.0% CI for Exp(B) | |||||||
---|---|---|---|---|---|---|---|
β | SE | Wald | p-Value | HR | Lower | Upper | |
Age (>75) Gender | 1.545 | 0.100 | 239.132 | <0.001 | 4.689 | 3.855 | 5.703 |
−0.112 | 0.078 | 2.032 | 0.154 | 0.894 | 0.767 | 1.043 | |
HTN | −0.121 | 0.091 | 1.779 | 0.182 | 0.886 | 0.741 | 1.059 |
T2DM | 0.201 | 0.073 | 7.503 | 0.006 | 1.223 | 1.059 | 1.412 |
CKD | 0.406 | 0.094 | 18.453 | <0.001 | 1.501 | 1.247 | 1.806 |
COPD | 0.528 | 0.108 | 23.973 | <0.001 | 1.695 | 1.372 | 2.093 |
PAD | 0.018 | 0.146 | 0.015 | 0.904 | 1.018 | 0.764 | 1.356 |
AMI | 0.405 | 0.120 | 11.493 | 0.001 | 1.500 | 1.186 | 1.895 |
Stroke | 0.438 | 0.099 | 19.478 | <0.001 | 1.550 | 1.276 | 1.882 |
HF | 0.394 | 0.083 | 22.626 | <0.001 | 1.483 | 1.261 | 1.744 |
DCM | 0.383 | 0.165 | 5.378 | 0.020 | 1.467 | 1.061 | 2.028 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Quesada, A.; Quesada-Ocete, J.; Quesada-Ocete, B.; del Moral-Ronda, V.; Jiménez-Bello, J.; Rubini-Costa, R.; Lavie, C.J.; Morin, D.P.; de la Guía-Galipienso, F.; Rubini-Puig, R.; et al. Gender-Based Clinical, Therapeutic Strategies and Prognosis Differences in Atrial Fibrillation. J. Cardiovasc. Dev. Dis. 2023, 10, 434. https://doi.org/10.3390/jcdd10100434
Quesada A, Quesada-Ocete J, Quesada-Ocete B, del Moral-Ronda V, Jiménez-Bello J, Rubini-Costa R, Lavie CJ, Morin DP, de la Guía-Galipienso F, Rubini-Puig R, et al. Gender-Based Clinical, Therapeutic Strategies and Prognosis Differences in Atrial Fibrillation. Journal of Cardiovascular Development and Disease. 2023; 10(10):434. https://doi.org/10.3390/jcdd10100434
Chicago/Turabian StyleQuesada, Aurelio, Javier Quesada-Ocete, Blanca Quesada-Ocete, Víctor del Moral-Ronda, Javier Jiménez-Bello, Ricardo Rubini-Costa, Carl J. Lavie, Daniel P. Morin, Fernando de la Guía-Galipienso, Ricardo Rubini-Puig, and et al. 2023. "Gender-Based Clinical, Therapeutic Strategies and Prognosis Differences in Atrial Fibrillation" Journal of Cardiovascular Development and Disease 10, no. 10: 434. https://doi.org/10.3390/jcdd10100434